E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group
2021; Lippincott Williams & Wilkins; Volume: 39; Issue: 28 Linguagem: Inglês
10.1200/jco.21.00944
ISSN1527-7755
AutoresRoisín M. Connolly, Fengmin Zhao, Kathy D. Miller, Min-Jung Lee, Richard Piekarz, Karen L. Smith, Ursa Brown‐Glaberman, Jennifer S. Winn, Bryan A. Faller, Adedayo A. Onitilo, Mark E. Burkard, G. Thomas Budd, Ellis Levine, Melanie Royce, Peter A. Kaufman, Alexandra Thomas, Jane B. Trepel, Antonio C. Wolff, Joseph A. Sparano,
Tópico(s)Breast Cancer Treatment Studies
ResumoEndocrine therapy resistance in advanced breast cancer remains a significant clinical problem that may be overcome with the use of histone deacetylase inhibitors such as entinostat. The ENCORE301 phase II study reported improvement in progression-free survival (PFS) and overall survival (OS) with the addition of entinostat to the steroidal aromatase inhibitor (AI) exemestane in advanced hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
Referência(s)